News

NIH inventors have developed the first known method of producing Regulatory B-cells (Bregs) ex-vivo. There is a great need to supplement the low population of Bregs in a patient suffering from an autoimmune disease where Breg levels are severely reduced, such as uveitis. This method involves
NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. The Th17
Register to attend a free NIH webinar on Wednesday January 28, 2026 at 11am ET. Attendees will learn about a new AI enhanced real-time echocardiography device and method to improve the analysis and quantification of heart related conditions, by automatically extracting predictive biomarkers from an